Profiling diarrhea-predominant irritable bowel syndrome (IBS-D) using stool-based RNAs
- Institution
- COLUMBIA UNIVERSITY HEALTH SCIENCES, NY
- Principal investigator
- Harris H Wang
- Funding
- $199K
- Duration
- 2024–2025
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY There are no tests to aid in the diagnosis of irritable bowel syndrome (IBS), which is the most common chronic gastrointestinal condition in the U.S. and is thought to arise in part from gut host-microbe interactions. Here, we propose to identify novel stool-based IBS biomarkers by sequencing exfoliated host gut cells and microbiota to non-invasively assess gene expression and microbiome changes in the gut. Our proposed research comprises two main aims. Firstly, we will establish a stool-based RNA sequencing method optimized for IBS and combine it with gut microbiome measurements. Secondly, we will apply our method to patient cohorts to identify stool RNA and gut microbiome features that could potentially diagnose and subtype IBS-D. This project will focus on diarrhea-predominant IBS (IBS-D), using test and validation patient cohorts to determine the accuracy of our method in distinguishing patients with IBS-D from healthy controls. We anticipate that this exploratory work will deliver a novel method to generate stool-based biomarkers for IBS-D, thereby improving diagnosis, phenotyping, and subsequent management of the disorder.
LOADING MOONBASE SCORE
Questions for COLUMBIA UNIVERSITY HEALTH SCIENCES
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Columbia University Health SciencesNot yet scored
Micron-scale Spatial Metagenomic Mapping of Microbial Biogeography in the Gastrointestinal Tract
Harris H Wang · $722K · 2017–2028
- NIH · Columbia University Health Sciences70
Causal Gene Prioritization in Systemic Sclerosis: Multi-Omics Analyses from Population Genetics to Single Cell Biology
Yiming Luo · $173K · 2025–2030
- NIH · Columbia University Health Sciences48
Metformin in Alzheimer's dementia Prevention (MAP)
Daniel F Hanley · $6.5M · 2019–2026